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Atypical and Anaplastic 
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Abstract
The aim of this chapter is to describe the usefulness of surgical technologies 
such as neuronavigation, intraoperative MRI, fluorescence-guided surgery and 
intraoperative monitoring as a tool do make neurosurgical procedures to brain 
tumors more safe and effective. The main topics to be explored are: history of the 
specific technique, indications and contra indications, description of the technique, 
real case examples, pros and cons. The focus on the discussion besides practical 
aspects is going to be relevant literature regarding impact of their use in avoidance 
of complications, improve in survival rates, cost-effectiveness, some tips and tricks 
acquired in the experience of our department.
Keywords: neurosurgical procedures, brain neoplasms, neuronavigation, 
fluorescence-guided surgery, magnetic resonance imaging
1. Introduction
Meningiomas originate from specialized meningothelial cells called arachnoid 
cap cells and correspond about up to 26% of all intracranial lesions. According 
to the World Health Organization (WHO), meningiomas are grouped in grade I 
(benign), grade II (atypical), and grade III (anaplastic) [1, 2]. This classification 
reflects the risk of recurrence and aggressive growth. Although uncommon, atypi-
cal corresponds to 4.7 to 20% of all meningiomas, while anaplastic for 1–2.8% [3, 4]. 
Symptomatology varies according to intracranial location and may be related to 
seizures and/or intracranial hypertension.
The standard treatment of grade II and grade III meningiomas involve total/
radical resection, respecting Simpson score, followed by adjuvant therapy with 
irradiation and, eventually, chemotherapy [5, 6]. Despite the treatment efforts, 
the evolution of aggressive meningiomas remains unsatisfactory due to the high 
rates of local recurrence and/or tumor progression [7]. These patients frequently 
underwent multiple surgical approaches during the course of the disease, increas-
ing the rates of postoperative complications as infection or CSF leakage.
With the continuous improvement of molecular and immunochemistry analysis, 
the paradigm for treatment of these tumors has been changing. In this chapter, the 
current management of aggressive/malignant meningiomas focusing on the new 
discovers in genetic/molecular and radiotherapy field is discussed.
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2. Materials and methods
In our database, we reviewed all meningiomas operated between 2012 and 2017 
in our institution to describe the epidemiologic characteristics of atypical and 
anaplastic subtypes, as well as an illustrative case focusing on the treatment and 
long-term follow-up. Also, literature was reviewed based on the WHO (2016) clas-
sification guided through genetic/molecular findings.
3. Results
A total of 170 new diagnosed patients with intracranial meningiomas under-
went microsurgical resection at the Neurological Institute of Curitiba (INC) 
between January 2012 and June 2017. A total of 94 (55%) tumors were classified 
as skull base tumors, 58 (34%) convexity, 10 (5.8%) parasagittal, and 8 (4.7%) 
falcine lesions.
In our series, 76.4% (130) of patients were female. Only six (3.5%) patients 
had atypical/anaplastic tumors with mean age of 53 years (Table 1). Simpson 
grade I resection (total tumor removal including resection of the underlying 
bone and associated dura mater) was achieved in all patients with malignant 
histology, and radiotherapy was reserved for progression. Only one patient with 
atypical meningioma received upfront radiotherapy because of high Ki-67 index. 
Any case of skull base meningioma exhibited progression to malignant subtypes 
in this series.
4. Illustrative case
58-year-old male has sporadic new onset headache, and magnetic resonance 
imaging (MRI) evidences enhanced parasagittal homogenous mass tumor with 
surrounding edema (Figure 1). Simpson grade I resection (Figure 2) was achieved 
at surgery, and histopathology confirmed atypical meningioma.
Immunohistochemistry of the first sample proved the trend toward malignant 
progression, with Ki-67 index of 70% in hot spots. Only focal positiveness for pro-
gesterone receptor was seen. Because of high Ki-67 index, adjuvant external beam 
radiotherapy (EBRT) was added to the treatment.
Table 1. 
Malignant meningioma at INC (2012–2017).
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After 1 year follow-up, recurrence at posterior border of previous surgical field 
was seen, and another gross total resection was necessary (Figure 3). The tumor 
expressed the same imaging characteristics of first analysis, with homogeneous 
contrast enhancement and peritumoral edema. Histopathological analyses con-
firmed again an atypical histology. At this time, chemotherapy with octreotide was 
introduced without response.
After 2 years from the first surgery, another recurrence was seen. At MRI, 
changes in previous pattern were seen with heterogeneous contrast enhancement 
and central necrosis (Figure 4). After another Simpson grade I tumor removal, 
progression to anaplastic meningioma was confirmed.
Figure 1. 
(A) Post-gadolinium-DTPA axial and coronal. (B) T1-weighted gradient echo (FSPGR) sequence with large 
parasagittal meningioma with partial occlusion of superior sagittal sinus.
Figure 2. 
Postoperative MRI with post-gadolinium-DTPA axial T1-weighted gradient echo (FSPGR) sequence exhibiting 
complete resection of parasagittal meningioma.
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In comparative analyses, immunohistochemistry evidenced an increase in Ki-67 
index from 70 to 90% of the cells. The epithelial membrane antigen (EMA), focal 
positive at first analysis, now expressed diffuse negativeness. Reduction in proges-
terone receptor expression was also documented.
Later, there was tumor progression again in two more occasions in an interval of 
8 months. Progressive neurological impairment and seizures due to motor cortex/
eloquent area involvement/gliosis were seemed, and tumor resection with extensive 
dural removal was performed both times (Figures 5 and 6). The patient underwent 
salvage irradiation, as the last recurrence was far from the original lesion. Two 
months after adjuvant treatment, the patient evolved with neurological worsening, 
dying due to clinical complications.
Figure 3. 
One-year-follow-up. (A) MRI. Axial post-gadolinium-DTPA T1-weighted gradient echo (FSPGR). 
(B) Flair sequences evidencing tumor recurrence adjacent to previous resection with the same features of 
original tumor.
Figure 4. 
Axial post-gadolinium-DTPA. (A) T1-weighted gradient echo (FSPGR) showing irregular contrast 
enhancement and tumoral necrosis. (B) Axial FLAIR magnetic resonance evidencing extensive peritumoral 
edema with changes in radiological aspect from original tumor.
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5. Discussion
About 90% of meningiomas are benign grade I tumors. Atypical meningiomas 
are uncommon (4.7–20% of all meningiomas), while anaplastic meningiomas 
account for only 1–2.8% of all meningiomas [1–4].
Figure 5. 
Axial post-gadolinium-DTPA. (A) T1-weighted gradient echo (FSPGR) showing tumor progression in 
multiple sites.
Figure 6. 
Intraoperative image showing the skull after multiple craniotomies.
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The WHO (2016) classification included brain invasion to the previous histo-
logical characteristic (4–19 mitotic figures and 3 of 5 histologic features): increased 
cellularity, small cells (tumor clusters with high nuclear/cytoplasmic ratio), promi-
nent nucleoli, and sheeting (loss of whorling or fascicular architecture and sponta-
neous necrosis) in the diagnosis of atypical meningiomas.
Anaplastic meningiomas are diagnosed with 20 or more mitotic figures and 
presence of frank sarcomatous or carcinomatous histology [3].
Despite of diagnostics criteria, the exact mechanism through how benign 
meningiomas progress to malignant subtypes remains unclear. Several molecular 
and genetic hypotheses have been postulated, but the real significance of these 
alterations is still speculative [8].
Evidence-based literature suggests that the extent of surgical resection, accord-
ingly to Simpson grade system, is the most important prognostic factor for good 
outcome among those patients harboring malignant meningioma [9].
In our series those cases, with atypical or anaplastic subtypes at primary surgery, 
demonstrated better response to Simpson grade I resection and adjuvant radiother-
apy than those cases that progressed from grade I subtype. Some genetic alteration 
related to progression, as previously reported in literature, can probably explain 
different evolution among tumors expressing the same histology like in these series 
[8, 10, 11].
Among those with atypical and anaplastic histology, tumor size and female 
gender have been related to poor outcome and presence of radiological features 
such as heterogeneous enhancement, peritumoral edema, and cyst formation, and 
absence of calcification have been implicated with lower median recurrence-free 
survival [9, 12].
In the illustrative case, the tumor progression was followed by changes in radio-
logical characteristics and immunohistochemical pattern. Possibly, in this case, the 
first immunohistochemistry analysis evidenced some characteristics of aggressive-
ness. In this scenario, Czonka et al. have previously published the utility of p53 gene 
expression and Ki-67 index in predicting meningioma progression [13].
Maximal safe resection with dural margins and bone hyperostosis removal stills 
the main point in the treatment of meningiomas, possibly reducing rates of progres-
sion and/or improving progression-free survival [14].
Radiotherapy is a special topic in the treatment of malignant meningiomas. 
Increase from 15 to 80% in 5 year progression-free survival was reported when 
EBRT was added to surgical resection for anaplastic meningioma. No consensus 
exists for atypical meningiomas, and EBRT has mostly been reserved for recurrence 
and progression [15, 16].
Due to the possibility of margin inclusion in irradiation field with EBRT, radio-
surgery is no longer indicated for malignant meningiomas. However, Lubgan et al. 
have reported excellent results with stereotactic radiotherapy when used as an 
adjuvant after gross total resection or as definitive treatment regime [17].
In the illustrative case, the lower progesterone receptor expression and higher 
Ki-67 index could probably predict the chance of progression and help in earlier 
adjuvant decision.
Several chemotherapy agents have been used for atypical and anaplastic 
meningiomas refractory to surgery and radiotherapy. In the largest revi-
sion, Kaley et al. found 47 publications using different chemotherapy agents 
(hydroxyurea, temozolomide, irinotecan, interferon-alpha, mifepristone, 
octreotide analogues, megestrol acetate, bevacizumab, imatinib, erlotinib, and 
gefitinib) with an average 6 month progression-free survival of 26%, concluding 
that the available chemotherapy agents provide poor outcomes for refractory 
malignant meningiomas [18].
7© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
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6. Conclusion
Atypical and anaplastic meningiomas remain challenging diseases, and no effec-
tive treatment is current available. Against literature evidence, we presume that 
the biological signature of this specific tumor is more important for evolution than 
previously reported prognostic factor. In this scenario, new studies aiming objective 
analyses of immunohistochemistry patterns and genetic profile of meningiomas 
are probably the next step for the comprehension of such complex neurosurgical 
pathology.
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